is recommended.vemurafenibvemurafenib and trimipramine both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.venlafaxinevenlafaxine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.vilanterol/fluticasone furoate inhaledtrimipramine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiatedtrimipramine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vortioxetinetrimipramine, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.xylometazolinetrimipramine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.yohimbeyohimbe, trimipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.yohimbinetrimipramine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.ziprasidonetrimipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (374)5-HTPtrimipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abirateroneabiraterone increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAabobotulinumtoxinA increases effects of trimipramine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .aclidiniumaclidinium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.albuteroltrimipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.albuterol and trimipramine both increase QTc interval. Use Caution/Monitor.alfentanilalfentanil and trimipramine both increase sedation. Use Caution/Monitor.alfuzosintrimipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and trimipramine both increase QTc interval. Use Caution/Monitor.almotriptanalmotriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.alprazolamalprazolam and trimipramine both increase sedation. Use Caution/Monitor.amifampridinetrimipramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amisulpridetrimipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylineamitriptyline and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amitriptyline and trimipramine both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and trimipramine both increase sedation. Use Caution/Monitor.amoxapineamoxapine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapine and trimipramine both increase sedation. Use Caution/Monitor.anagrelideanagrelide and trimipramine both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.apomorphinetrimipramine and apomorphine both increase sedation. Use Caution/Monitor.apomorphine and trimipramine both increase QTc interval. Use Caution/Monitor.arformoteroltrimipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arformoterol and trimipramine both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and trimipramine both increase sedation. Use Caution/Monitor.aripiprazole and trimipramine both increase QTc interval. Use Caution/Monitor.armodafiniltrimipramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.asenapineasenapine and trimipramine both increase QTc interval. Use Caution/Monitor.asenapine transdermalasenapine transdermal and trimipramine both increase QTc interval. Use Caution/Monitor.atazanaviratazanavir increases levels of trimipramine by unspecified interaction mechanism. Use Caution/Monitor.atazanavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atomoxetineatomoxetine and trimipramine both increase QTc interval. Use Caution/Monitor.atracuriumatracurium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineatropine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.azelastineazelastine and trimipramine both increase sedation. Use Caution/Monitor.azithromycintrimipramine and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenbaclofen and trimipramine both increase sedation. Use Caution/Monitor.bedaquilinetrimipramine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsbelladonna alkaloids and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opium and trimipramine both increase sedation. Use Caution/Monitor.benperidolbenperidol and trimipramine both increase sedation. Use Caution/Monitor.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, trimipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.benzphetaminetrimipramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benztropinebenztropine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholbethanechol increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.brompheniraminebrompheniramine and trimipramine both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and trimipramine both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and trimipramine both increase sedation. Use Caution/Monitor.buprenorphine subdermal implanttrimipramine, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.buprenorphine, long-acting injectiontrimipramine, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.bupropiontrimipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.bupropion will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital and trimipramine both increase sedation. Use Caution/Monitor.butalbitalbutalbital and trimipramine both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and trimipramine both increase sedation. Use Caution/Monitor.caffeinetrimipramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cannabidiolcannabidiol will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider reducing the dose of sensitive CYP2C19 substrates, as clinically appropriate, when coadministered with cannabidiol. carbacholcarbachol increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbinoxaminecarbinoxamine and trimipramine both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and trimipramine both increase sedation. Use Caution/Monitor.cenobamatecenobamate will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Consider a dose reduction of CYP2C19 substrates, as clinically appropriate, when used concomitantly with cenobamate. cenobamate, trimipramine. Either increases effects of the other by sedation. Use Caution/Monitor.ceritinibceritinib and trimipramine both increase QTc interval. Use Caution/Monitor.ceritinib will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cevimelinecevimeline increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chloral hydratechloral hydrate and trimipramine both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and trimipramine both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and trimipramine both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and trimipramine both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and trimipramine both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and trimipramine both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clarithromycinclarithromycin will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clemastineclemastine and trimipramine both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. trimipramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineclomipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and trimipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and trimipramine both increase sedation. Use Caution/Monitor.clorazepateclorazepate and trimipramine both increase sedation. Use Caution/Monitor.clozapineclozapine and trimipramine both increase sedation. Use Caution/Monitor.clozapine and trimipramine both increase QTc interval. Use Caution/Monitor.cobicistatcobicistat will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant responsecobicistat will increase the level or effect of trimipramine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat. cobicistat will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cocaine topicaltrimipramine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.codeinecodeine and trimipramine both increase sedation. Use Caution/Monitor.crizotinibcrizotinib and trimipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.crizotinib increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemercrofelemer increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclizine and trimipramine both increase sedation. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprine and trimipramine both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and trimipramine both increase sedation. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dantrolenedantrolene and trimipramine both increase sedation. Use Caution/Monitor.daridorexanttrimipramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.darunavirdarunavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibtrimipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.debrisoquinetrimipramine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.degarelixdegarelix and trimipramine both increase QTc interval. Use Caution/Monitor.desfluranedesflurane and trimipramine both increase sedation. Use Caution/Monitor.desflurane and trimipramine both increase QTc interval. Use Caution/Monitor.desipraminedesipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and trimipramine both increase sedation. Use Caution/Monitor.deutetrabenazinetrimipramine and deutetrabenazine both increase sedation. Use Caution/Monitor.deutetrabenazine and trimipramine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and trimipramine both increase sedation. Use Caution/Monitor.dexfenfluraminetrimipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.dexmedetomidinedexmedetomidine and trimipramine both increase sedation. Use Caution/Monitor.dexmethylphenidatetrimipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetaminetrimipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.trimipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.dextroamphetamine transdermaltrimipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.dextromoramidedextromoramide and trimipramine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and trimipramine both increase sedation. Use Caution/Monitor.diazepamdiazepam and trimipramine both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dicyclominedicyclomine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diethylpropiontrimipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and trimipramine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and trimipramine both increase sedation. Use Caution/Monitor.dihydroergotaminetrimipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasaltrimipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.diltiazemdiltiazem